GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (FRA:NV3P) » Definitions » Shiller PE Ratio

Nanoviricides (FRA:NV3P) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to . Start your Free Trial

What is Nanoviricides Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanoviricides Shiller PE Ratio Historical Data

The historical data trend for Nanoviricides's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Shiller PE Ratio Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanoviricides Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanoviricides's Shiller PE Ratio

For the Biotechnology subindustry, Nanoviricides's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Shiller PE Ratio falls into.



Nanoviricides Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nanoviricides's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Nanoviricides's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.147/131.7762*131.7762
=-0.147

Current CPI (Mar. 2024) = 131.7762.

Nanoviricides Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -2.061 100.560 -2.701
201409 0.310 100.428 0.407
201412 -0.649 99.070 -0.863
201503 -0.370 99.621 -0.489
201506 -0.356 100.684 -0.466
201509 -0.356 100.392 -0.467
201512 -0.918 99.792 -1.212
201603 -1.616 100.470 -2.120
201606 -0.534 101.688 -0.692
201609 -0.891 101.861 -1.153
201612 -0.569 101.863 -0.736
201703 -0.935 102.862 -1.198
201706 -0.712 103.349 -0.908
201709 -0.503 104.136 -0.637
201712 -0.676 104.011 -0.856
201803 -0.487 105.290 -0.610
201806 -0.377 106.317 -0.467
201809 -0.454 106.507 -0.562
201812 -0.563 105.998 -0.700
201903 -0.522 107.251 -0.641
201906 -0.513 108.070 -0.626
201909 -0.372 108.329 -0.453
201912 -0.450 108.420 -0.547
202003 -1.122 108.902 -1.358
202006 0.053 108.767 0.064
202009 -0.187 109.815 -0.224
202012 -0.181 109.897 -0.217
202103 -0.160 111.754 -0.189
202106 -0.149 114.631 -0.171
202109 -0.196 115.734 -0.223
202112 -0.150 117.630 -0.168
202203 -0.145 121.301 -0.158
202206 -0.142 125.017 -0.150
202209 -0.141 125.227 -0.148
202212 -0.142 125.222 -0.149
202303 -0.140 127.348 -0.145
202306 -0.286 128.729 -0.293
202309 -0.159 129.860 -0.161
202312 -0.165 129.419 -0.168
202403 -0.147 131.776 -0.147

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nanoviricides  (FRA:NV3P) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nanoviricides Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (FRA:NV3P) Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides (FRA:NV3P) Headlines

No Headlines